The British molecular genetics company recently announced a menu update for its SureSeq myPanel NGS Custom Cancer Panel offering.
Angsana will support a Phase 2 basket trial for a tyrosine kinase inhibitor that targets tumors harboring TRK, ROS1, and ALK fusions.
The company is preparing a blood-based test for early-stage pancreatic cancer that it hopes to have on the market by 2019.
The company's new blood-based test is the first clinical test offering that the company will be offering at its New York-based CLIA laboratory.
N-of-One will identify the most relevant therapeutic options for each patient tested with Admera's 64-gene oncology panel.
Full-year revenues fell 22 percent, which the company said was due to a decrease in the number of kits being returned for processing.
The company's recent experience demonstrates the impasse between genetic test developers and payors about the types of clinical evidence needed for coverage.
The companies are co-developing an assay that differentiates previously infected, seropositive Lyme disease patients from newly infected individuals.
OmniSeq's goal is to make cancer genomic testing available to institutions, including comprehensive cancer centers, oncology practices, and community oncology groups.
NEW YORK (GenomeWeb) – Cancer Genetics today said that it will collaborate with a researcher at Keck Medicine of the University of Southern California to identify genomic markers of diffuse large B-cell lymphoma.
Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.
The New York Times reports that a number of companies and research institutes are pursuing gene therapies.
Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.
In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.